Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Lilly partners on Rigel’s RIPK1 inhibitors

by Ryan Cross
February 28, 2021 | A version of this story appeared in Volume 99, Issue 7

 

Eli Lilly and Company will collaborate with Rigel Pharmaceuticals to develop a small-molecule inhibitor of RIPK1, a kinase involved in cell death and inflammation. Lilly will pay Rigel $125 million up front and up to $835 in milestone payments. The pair will test the molecule in Phase 2 trials of autoimmune and inflammatory diseases this year. RIPK1 is also linked to neurodegenerative diseases including Alzheimer’s and amyotrophic lateral sclerosis, and Lilly plans tests of a brain-penetrating RIPK1 inhibitor to treat central nervous system diseases.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.